---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000145"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:54:11.886988+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Salarius regains Nasdaq equity compliance; fully compliant ahead of Decoy merger

## Summary
- Received Nasdaq letter on Oct 10, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).
- Now fully compliant with all Nasdaq listing requirements, having also regained bid price compliance on Sept 9, 2025.
- Subject to a Mandatory Panel Monitor for one year from Oct 10, 2025; noncompliance could lead to delisting without a cure period.
- Planned merger with Decoy Therapeutics (announced Jan 13, 2025) remains on track; combined company to be named Decoy Therapeutics.
- Post-merger pipeline includes pan-coronavirus antiviral IND filing within 12 months and data from MD Anderson seclidemstat study.

## SEC filing metadata
- accession: 0001615219-25-000145
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000145/0001615219-25-000145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000145/flks-20251010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000145
- JSON: https://secwatch.observer/filing/0001615219-25-000145.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.